23558-58-9

Upstream product

• 3056-18-6 (2R,3R,4R,5R)-4-(acetyloxy)-2-[(acetyloxy)methyl]-5-(2,6-dichloro-9H-purin-9-yl)tetrahydro-3-furanyl acetate 
• 156-34-3 l-amphetamine 
• 15373-23-6 (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate 

Relevant academic research and scientific papers

Purine derivatives

A compound of formula (I), or a pharmaceutically acceptable salt thereof: STR1 wherein X is hydrogen, amino, halogen, hydroxy, lower alkoxy or lower alkyl andR 1 is STR2 wherein Y is methylene or a valence bond, R 2 and R 5 is H or lower, straight or branched alkyl,R 3 is H or lower alkyl, orR 2 and R 3 can together form a cyclobutyl, cyclopentyl, cyclohexyl or phenyl ring,Z is oxygen, methylene, sulphur, sulphonyl or a valence bond,R 4 is H, lower alkyl, aralkyl, a mono or bicyclic aromatic system optionally substituted with various groups.The compounds have been found useful for treating central nervous system ailments.

Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.

Radioligand binding studies of N6-substituted adenosines at the A1 and A2 adenosine receptors of rat brain cortex and rat brain striatum, respectively, show that a 2-chloro substituent does not consistently change the affinity or the selectivity of these analogues for the A1 receptor. A 2-chloro substituent lowers the characteristic stereoselectivity of the A1 receptor toward the R diastereomer of N6-(1-phenyl-2-propyl)adenosine. A 2-chloro substituent consistently increases potency of N6-substituted adenosines as agonists at an adenosine A2 receptor stimulatory to adenylate cyclase in PC12 cell membranes.